Recent advances in immunology have underscored the pivotal role of the transcription factor RORγt in orchestrating the differentiation of Th17 cells and the consequent production of proinflammatory ...
Monlunabant shows significant and clinically meaningful weight loss over 16 weeks in patients with obesity and metabolic ...
(A) GPCR agonists increase the proportion of active receptor states; inverse agonists decrease the proportion of active receptor states; and antagonists inhibit the action of other ligands. (B) In ...
CRB-913 is a member of a new class of peripherally restricted CB1 inverse agonists designed to have reduced brain penetration. Pre-clinical models have shown CRB-913 to be 15-fold less brain penetrant ...
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabant SAD/MAD Phase 1 trial scheduled ...
Corbus Pharmaceuticals reports no neuropsychiatric events in CRB-913 trial, advancing to multiple ascending dose phase. Study completion projected for Q3 2025. Corbus Pharmaceuticals Holdings Inc. has ...
NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the initiation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback